Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9638632 | 0.98 | NR1H4 (0.62) | NR1H4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13753805 | 0.91 | TP53 (0.77) | NR1H4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL930908 | 0.87 | ROCK2 (0.76) | NR1H4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15434476 | 0.87 | TAS1R3 (0.63) | NR1H4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL17676475 | 0.87 | LMNA (0.54) | NR1H4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL25022849 | 0.87 | TAS1R3 (0.56) | NR1H4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13216467 | 0.87 | RAB9A (0.62) | RAB9AMEN1KMT2ATP53POLB | |
| SCHEMBL90417 | 0.87 | TP53 (0.67) | NR1H4RAB9AMEN1KMT2ATP53 | |
| SCHEMBL1931948 | 0.85 | L3MBTL1 (0.59) | NR1H4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13702311 | 0.85 | LMNA (0.52) | NR1H4NPC1RAB9ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015108-A1 | Aqueous Buffered Fluoride-Containing Etch Residue Removers and Cleaners | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2011-01-20 | — | — | US | claimed |
| US-7807613-B2 | Aqueous buffered fluoride-containing etch residue removers and cleaners | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2010-10-05 | — | — | US | claimed |
| US-20040266637-A1 | Aqueous buffered fluoride-containing etch residue removers and cleaners | VERSUM MATERIALS US, LLC | 2004-12-30 | — | — | US | claimed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| WO-2017106607-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| CN-101489988-A | Process for alkenylation of carboxamides | BASF AG (DE) | 2009-07-22 | — | — | CN | disclosed |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7390830-B1 | Remedies or prophylactics for diseases in association with chemokines | TEIJIN LIMITED (JP) | 2008-06-24 | — | — | US | disclosed |
| US-5378702-A | Thiadizinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | disclosed |
| CN-1084172-A | Thiadiazinone | MERCK PATENT GMBH (DE) | 1994-03-23 | — | — | CN | disclosed |
| EP-0579077-A2 | 1,3,4-Thiadiazinones for the treatment of cardiovascular diseases | MERCK PATENT GmbH (DE) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NR1H4 36/4885NPC1 239/4885RAB9A 774/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NR1H4 47/4885NPC1 392/4885RAB9A 903/4885 |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | PRMT5, CYC1, CBR3 | NR1H4 3173/4885NPC1 3667/4885RAB9A 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.